Immunovant falls as eye disease therapy fails in late-stage studies

Immunovant

02/04/2026 10:32

** Shares of Immunovant IMVT.O fall 12.1% to $22.07 premarket

** Co says based on the pre-specified statistical analysis plan, two late-stage studies failed to meet their main goals

** Co was studying its experimental therapy batoclimab for thyroid eye disease

** Thyroid eye disease is an autoimmune inflammatory disorder often associated with Graves' disease, where the immune system attacks tissues behind the eye, causing swelling, inflammation, and potential vision changes

** Co intends to review future plans for the development of batoclimab with its partner HanAll Biopharma Co 009420.KS and to provide an update on the program at a future date

** Up to last close, stock down 1.3% YTD

 (Reporting by Sriparna Roy in Bengaluru)

 ((Sriparna.Roy@thomsonreuters.com;))